Vincent C O Njar
6PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Mar 28, 2025
Correction: Maranto et al. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers 2020, 12, 3412.Cristina Maranto, Vindhya Udhane, Jing Jia
|Feb 26, 2025
Thermal proteome profiling and proteome analysis using high-definition mass spectrometry demonstrate modulation of cholesterol biosynthesis by next-generation galeterone analog VNPP433-3β in castration-resistant prostate cancer.Retheesh S Thankan, Elizabeth Thomas, Mehari M Weldemariam
|Feb 25, 2023
Targeted Degradation of Androgen Receptor by VNPP433-3β in Castration-Resistant Prostate Cancer Cells Implicates Interaction with E3 Ligase MDM2 Resulting in Ubiquitin-Proteasomal Degradation.Elizabeth Thomas, Retheesh S Thankan, Puranik Purushottamachar
|Sep 09, 2022
Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models.Elizabeth Thomas, Retheesh S Thankan, Puranik Purushottamachar
|Nov 21, 2020
Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo.Cristina Maranto, Vindhya Udhane, Jing Jia
|Oct 27, 2019
Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo.Andrew K Kwegyir-Afful, Senthilmurugan Ramalingam, Vidya P Ramamurthy
Pageof 1
